Responses to polatuzumab vedotin in the bridging cohort
| Best responses polatuzumab vedotin . | n . |
|---|---|
| Intended CAR T-cell therapy, n = 41 | |
| Proceeded to CAR T-cell therapy after pola bridging, n = 21 (51.2%) | |
| CR | 0 |
| PR | 5 |
| Clinical response | 2 |
| SD/clinical stable disease | 7 |
| MR | 2 |
| PD/clinical progression | 5 |
| Proceeded to CAR T-cell therapy after alternative bridging, n = 7 (17.1%) | |
| PD/clinical progression | 7 |
| Treated palliatively, n = 13 (31.7%) | |
| CR* | 1 |
| Clinical response† | 2 |
| MR | 1 |
| PD/clinical progression | 6 |
| Not evaluable | 3 |
| Intended alloHCT, n = 10 | |
| Proceeded to alloHCT after pola bridging, n = 5 | |
| CR | 1 |
| PR | 3 |
| SD | 1 |
| Proceeded to alloHCT after alternative bridging, n = 2 | |
| SD | 1 |
| PD | 1 |
| Treated palliatively, n = 3 | |
| PR† | 1 |
| Clinical response† | 1 |
| MR | 1 |
| Best responses polatuzumab vedotin . | n . |
|---|---|
| Intended CAR T-cell therapy, n = 41 | |
| Proceeded to CAR T-cell therapy after pola bridging, n = 21 (51.2%) | |
| CR | 0 |
| PR | 5 |
| Clinical response | 2 |
| SD/clinical stable disease | 7 |
| MR | 2 |
| PD/clinical progression | 5 |
| Proceeded to CAR T-cell therapy after alternative bridging, n = 7 (17.1%) | |
| PD/clinical progression | 7 |
| Treated palliatively, n = 13 (31.7%) | |
| CR* | 1 |
| Clinical response† | 2 |
| MR | 1 |
| PD/clinical progression | 6 |
| Not evaluable | 3 |
| Intended alloHCT, n = 10 | |
| Proceeded to alloHCT after pola bridging, n = 5 | |
| CR | 1 |
| PR | 3 |
| SD | 1 |
| Proceeded to alloHCT after alternative bridging, n = 2 | |
| SD | 1 |
| PD | 1 |
| Treated palliatively, n = 3 | |
| PR† | 1 |
| Clinical response† | 1 |
| MR | 1 |
Objective responses specified as CR, PR, SD, MR, and PD were assessed by CT. In absence of CT scans, response assessment was based on physician’s clinical judgment including results of physical examination and laboratory assessment and documented as clinical response, clinical stable disease, or clinical progression. Response assessment with CT scans was available in 68.6% (35/51) patients. The median time of first CT response assessment was 39 d (range, 9-124 d). The median time to best CT response was 42 d (range, 9-200 d).
MR, mixed response; PD, progressive disease; SD, stable disease.
Patient was followed up in palliative intention because of a failed T-cell apheresis.
Patients developed progressive disease during further treatment.